[SCHEDULE 13G/A] CytomX Therapeutics, Inc. Amended Passive Investment Disclosure
OrbiMed reports 2.1% stake in CytomX
OrbiMed Advisors LLC reports beneficial ownership of 3,525,650 shares of CytomX Therapeutics, Inc. common stock, representing 2.1% of the class as of 12/31/2025.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
OrbiMed Advisors LLC reports beneficial ownership of 3,525,650 shares of CytomX Therapeutics, Inc. common stock, representing 2.1% of the class as of 12/31/2025. OrbiMed has shared voting and dispositive power over these shares, which it holds on behalf of other persons entitled to dividends and sale proceeds.
The filing notes this is ownership of 5 percent or less of CytomX’s common stock. OrbiMed states the securities are not held for the purpose of changing or influencing control of CytomX, and its management committee members each disclaim beneficial ownership of the reported shares.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of CytomX (CTMX) does OrbiMed Advisors LLC report owning?
OrbiMed Advisors LLC reports beneficially owning 2.1% of CytomX common stock. This equates to 3,525,650 shares as of December 31, 2025, placing OrbiMed below the 5% threshold that typically signals a larger, potentially more influential stake.
How many CytomX (CTMX) shares does OrbiMed Advisors LLC control voting for?
OrbiMed Advisors LLC reports shared voting power over 3,525,650 CytomX shares and no sole voting power. It also has shared dispositive power over the same amount, meaning decisions to sell or hold these shares are made jointly under OrbiMed’s investment authority.
Is OrbiMed Advisors LLC’s CytomX (CTMX) stake intended to influence company control?
No. OrbiMed certifies the CytomX shares were not acquired and are not held to change or influence control of the company. The position is reported on a passive basis under Schedule 13G/A, rather than as an activist or control-seeking stake.
On whose behalf does OrbiMed Advisors LLC hold its CytomX (CTMX) shares?
OrbiMed holds 2.1% of CytomX common stock in the aggregate on behalf of other persons who are entitled to receive dividends and sale proceeds. OrbiMed exercises investment and voting power through a management committee overseeing these client or fund holdings.
Do OrbiMed’s committee members personally claim ownership of CytomX (CTMX) shares?
No. The management committee members—Carl L. Gordon, Sven H. Borho, and W. Carter Neild—each disclaim beneficial ownership of the reported CytomX shares. The stake is attributed to OrbiMed Advisors LLC acting in its investment management capacity, not to the individuals personally.
What key date applies to OrbiMed Advisors LLC’s CytomX (CTMX) ownership report?
The relevant event date for OrbiMed’s CytomX ownership is December 31, 2025. As of that date, OrbiMed reports beneficial ownership of 3,525,650 shares, or 2.1% of the outstanding common stock, under this amended Schedule 13G filing.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
CytomX Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.00001 per share
(Title of Class of Securities)
23284F105
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
23284F105
1
Names of Reporting Persons
OrbiMed Advisors LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,525,650.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,525,650.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,525,650.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.1 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
CytomX Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
151 Oyster Point Blvd., Suite 400 South San Francisco, California, 94080
Item 2.
(a)
Name of person filing:
OrbiMed Advisors LLC
(b)
Address or principal business office or, if none, residence:
601 Lexington Avenue, 54th Floor New York, NY 10022
(c)
Citizenship:
Delaware
(d)
Title of class of securities:
Common Stock, par value $0.00001 per share
(e)
CUSIP No.:
23284F105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
3,525,650
(b)
Percent of class:
2.1%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
3,525,650
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
3,525,650
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Reporting Person holds 2.1% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC exercises investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
